DNA methylation of GHSR, GNG4, HOXD9 and SALL3 is a common epigenetic alteration in thymic carcinoma

Kishibuchi,Reina; Kondo,Kazuya; Soejima,Shiho; Tsuboi,Mitsuhiro; Kajiura,Koichiro; Kawakami,Yukikiyo; Kawakita,Naoya; Sawada,Toru; Toba,Hiroaki; Yoshida,Mitsuteru; Takizawa,Hiromitsu; Tangoku,Akira

doi:10.3892/ijo.2019.4915

DNA methylation of GHSR, GNG4, HOXD9 and SALL3 is a common epigenetic alteration in thymic carcinoma

Authors:
- Reina Kishibuchi
- Kazuya Kondo
- Shiho Soejima
- Mitsuhiro Tsuboi
- Koichiro Kajiura
- Yukikiyo Kawakami
- Naoya Kawakita
- Toru Sawada
- Hiroaki Toba
- Mitsuteru Yoshida
- Hiromitsu Takizawa
- Akira Tangoku
View Affiliations

Affiliations: Department of Oncological Medical Services, Graduate School of Biomedical Sciences, Tokushima University, Tokushima 770‑8509, Japan, Department of Thoracic, Endocrine Surgery and Oncology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima 770‑8503, Japan
Published online on: November 18, 2019 https://doi.org/10.3892/ijo.2019.4915
Pages: 315-326

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymic epithelial tumors comprise thymoma, thymic carcinoma and neuroendocrine tumors of the thymus. Recent studies have revealed that the incidence of somatic non‑synonymous mutations is significantly higher in thymic carcinoma than in thymoma. However, limited information is currently available on epigenetic alterations in these types of cancer. In this study, we thus performed genome‑wide screening of aberrantly methylated CpG islands in thymoma and thymic carcinoma using Illumina HumanMethylation450 K BeadChip. We identified 92 CpG islands significantly hypermethylated in thymic carcinoma in relation to thymoma and selected G protein subunit gamma 4 (GNG4), growth hormone secretagogue receptor (GHSR), homeobox D9 (HOXD9) and spalt like transcription factor 3 (SALL3), which are related to cancer. We examined the promoter methylation of 4 genes in 46 thymic epithelial tumors and 20 paired thymus tissues using bisulfite pyrosequencing. Promoter methylation was significantly higher in thymic carcinoma than in thymoma and revealed a high discrimination between thymic carcinoma and thymoma in all 4 genes. Promoter methylation was higher in thymic carcinoma than in the thymus. No significant differences were observed in the promoter methylation of GNG4, HOXD9, or SALL3 between thymoma and the thymus. The promoter methylation of the 4 genes was not significantly higher in advanced‑stage tumors than in early‑stage tumors in all thymic epithelial tumors. Among the 4 genes, relapse‑free survival was significantly worse in tumors with a higher DNA methylation than in those with a lower DNA methylation in all thymic epithelial tumors. Moreover, relapse‑free survival was significantly worse in thymomas with a higher DNA methylation of HOXD9 and SALL3 than in those with a lower DNA methylation. On the whole, the findings of this study indicated that the promoter methylation of cancer‑related genes was significantly higher in thymic carcinoma than in thymoma and the thymus. This is a common epigenetic alteration of high diagnostic value in thymic carcinoma and may be involved in the carcinogenesis of thymic carcinoma. However, epigenetic alterations in the 3 genes, apart from GHSR, are not involved in the tumorigenesis of thymoma.

View Figures

View References

1	Kondo K: Therapy for thymic epithelial tumors. Gen Thorac Cardiovasc Surg. 62:468–474. 2014. View Article : Google Scholar : PubMed/NCBI
2	Travis WD, Brambilla E, Burke AP, Marx A and Nicholson AG: WHO classification of tumours of the lung, pleura, thymus and heart. World Health Organization classification of tumours. Bosman FT, Jaffe ES, Lakhani SR and Ohgaki H: 4th edition. IARC Press; Lyon: pp. 183–243. 2015
3	Shimosato Y, Mukai K and Matsuno Y: Tumors of the mediastinum. AFIP Atlas of tumor pathology, Series 4. Armed Forces Institute of Pathology Washington, DC: 2010
4	Wang Y, Thomas A, Lau C, Rajan A, Zhu Y, Killian JK, Petrini I, Pham T, Morrow B, Zhong X, et al: Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep. 4:73362014. View Article : Google Scholar : PubMed/NCBI
5	Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, et al: The integrated genomic landscape of thymic epithelial tumors. Cancer Cell. 33:244–258.e10. 2018. View Article : Google Scholar : PubMed/NCBI
6	Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, et al: A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet. 46:844–849. 2014. View Article : Google Scholar : PubMed/NCBI
7	Hirose Y, Kondo K, Takizawa H, Nagao T, Nakagawa Y, Fujino H, Taba H, Kenzaki K, Sakiyama S and Tangoku A: Aberrant methylation of tumour-related genes in thymic epithelial tumours. Lung Cancer. 64:155–159. 2009. View Article : Google Scholar
8	Mokhtar M, Kondo K, Namura T, Ali AH, Fujita Y, Takai C, Takizawa H, Nakagawa Y, Toba H, Kajiura K, et al: Methylation and expression profiles of MGMT gene in thymic epithelial tumors. Lung Cancer. 83:279–287. 2014. View Article : Google Scholar : PubMed/NCBI
9	Detterbeck FC, Nicholson AG, Kondo K, Van Schil P and Moran C: The Masaoka-Koga stage classification for thymic malignancies: Clarification and definition of terms. J Thorac Oncol. 6(7 Suppl 3): S1710–S1716. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kajiura K, Masuda K, Naruto T, Kohmoto T, Watanabe M, Tsuboi M, Takizawa H, Kondo K, Tangoku A and Imoto I: Frequent silencing of the candidate tumor suppressor TRIM58 by promoter methylation in early-stage lung adenocarcinoma. Oncotarget. 8:2890–2905. 2017. View Article : Google Scholar :
11	Moskalev EA, Jandaghi P, Fallah M, Manoochehri M, Botla SK, Kolychev OV, Nikitin EA, Bubnov VV, von Knebel Doeberitz M, Strobel O, et al: GHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers. Oncotarget. 6:4418–4427. 2015. View Article : Google Scholar : PubMed/NCBI
12	Pal J, Patil V, Mondal B, Shukla S, Hegde AS, Arivazhagan A, Santosh V and Somasundaram K: Epigenetically silenced GNG4 inhibits SDF1α/CXCR4 signaling in mesenchymal glioblastoma. Genes Cancer. 7:136–147. 2016.PubMed/NCBI
13	Marzese DM, Scolyer RA, Huynh JL, Huang SK, Hirose H, Chong KK, Kiyohara E, Wang J, Kawas NP, Donovan NC, et al: Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet. 23:226–238. 2014. View Article : Google Scholar
14	Misawa K, Mochizuki D, Imai A, Misawa Y, Endo S, Mima M, Kawasaki H, Carey TE and Kanazawa T: Epigenetic silencing of SALL3 is an independent predictor of poor survival in head and neck cancer. Clin Epigenetics. 9:642017. View Article : Google Scholar :
15	Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H and Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 402:656–660. 1999. View Article : Google Scholar : PubMed/NCBI
16	Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, et al: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 273:974–977. 1996. View Article : Google Scholar : PubMed/NCBI
17	Lin TC and Hsiao M: Ghrelin and cancer progression. Biochim Biophys Acta Rev Cancer. 1868:51–57. 2017. View Article : Google Scholar : PubMed/NCBI
18	Jandaghi P, Hoheisel JD and Riazalhosseini Y: GHSR hyper-methylation: A promising pan-cancer marker. Cell Cycle. 14:689–690. 2015. View Article : Google Scholar :
19	Clapham DE and Neer EJ: G protein beta gamma subunits. Annu Rev Pharmacol Toxicol. 37:167–203. 1997. View Article : Google Scholar : PubMed/NCBI
20	Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, Johnson CM and Maher ER: Identification of novel VHL target genes and relationship to hypoxic response pathways. Oncogene. 24:4549–4558. 2005. View Article : Google Scholar : PubMed/NCBI
21	McGinnis W and Krumlauf R: Homeobox genes and axial patterning. Cell. 68:283–302. 1992. View Article : Google Scholar : PubMed/NCBI
22	Shah N and Sukumar S: The Hox genes and their roles in oncogenesis. Nat Rev Cancer. 10:361–371. 2010. View Article : Google Scholar : PubMed/NCBI
23	Tabuse M, Ohta S, Ohashi Y, Fukaya R, Misawa A, Yoshida K, Kawase T, Saya H, Thirant C, Chneiweiss H, et al: Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells. Mol Cancer. 10:602011. View Article : Google Scholar : PubMed/NCBI
24	Lv X, Li L, Lv L, Qu X, Jin S, Li K, Deng X, Cheng L, He H and Dong L: HOXD9 promotes epithelial-mesenchymal transition and cancer metastasis by ZEB1 regulation in hepatocellular carcinoma. J Exp Clin Cancer Res. 34:1332015. View Article : Google Scholar : PubMed/NCBI
25	Kohlhase J, Hausmann S, Stojmenovic G, Dixkens C, Bink K, Schulz-Schaeffer W, Altmann M and Engel W: SALL3, a new member of the human spalt-like gene family, maps to 18q23. Genomics. 62:216–222. 1999. View Article : Google Scholar : PubMed/NCBI
26	Strathdee G, Sutherland R, Jonsson JJ, Sataloff R, Kohonen-Corish M, Grady D and Overhauser J: Molecular characterization of patients with 18q23 deletions. Am J Hum Genet. 60:860–868. 1997.PubMed/NCBI
27	Yang XX, Sun JZ, Li FX, Wu YS, Du HY, Zhu W, Li XH and Li M: Aberrant methylation and downregulation of sall3 in human hepatocellular carcinoma. World J Gastroenterol. 18:2719–2726. 2012. View Article : Google Scholar : PubMed/NCBI
28	Shikauchi Y, Saiura A, Kubo T, Niwa Y, Yamamoto J, Murase Y and Yoshikawa H: SALL3 interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepatocellular carcinoma. Mol Cell Biol. 29:1944–1958. 2009. View Article : Google Scholar : PubMed/NCBI
29	Wei X, Zhang S, Cao D, Zhao M, Zhang Q, Zhao J, Yang T, Pei M, Wang L, Li Y and Yang X: Aberrant hypermethylation of SALL3 with HPV involvement contributes to the carcinogenesis of cervical cancer. PLoS One. 10:e01457002015. View Article : Google Scholar : PubMed/NCBI